Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor

Oncogene

Volumn 33, Issue 29, 2014, Pages 3878-3885

  Liu, J ^a   Visser Grieve, S ^a   Boudreau, J ^a   Yeung, B ^a   Lo, S ^a   Chamberlain, G ^a   Yu, F ^a   Sun, T ^a,b   Papanicolaou, T ^a   Lam, A ^a   Yang, X ^a   Chin Sang, I ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

C. elegans; cancer; genetics; insulin signaling; PTEN; tumour suppressor

Indexed keywords

INSULIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; BREAST CANCER CELL LINE; CAENORHABDITIS ELEGANS; CANCER RISK; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE CONTROL; GENE REPRESSION; GENETIC RISK; HUMAN; HUMAN CELL; HYPERINSULINEMIA; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CAENORHABDITIS ELEGANS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; AXONS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL LINE; GENE EXPRESSION; HUMANS; INSULIN; INTESTINES; MODELS, BIOLOGICAL; MUTATION; NEURONS; PROTEIN BINDING; PTEN PHOSPHOHYDROLASE; RECEPTOR, INSULIN;

EID: 84904645959     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.347     Document Type: Article

References (47)

1. Finch CE, Ruvkun G. The genetics of aging. Annu Rev Genomics Hum Genet 2001; 2: 435-462
2. Yang X, Xu T. Molecular mechanism of size control in development and human diseases. Cell Res 2011; 21: 715-729
3. Song J, Wu L, Chen Z, Kohanski RA, Pick L. Axons guided by insulin receptor in Drosophila visual system. Science 2003; 300: 502-505
4. Kenyon C. A pathway that links reproductive status to lifespan in Caenorhabditis elegans. Ann NY Acad Sci 2010; 1204: 156-162
5. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18: R125-R147
6. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011; 152: 2546-2551
7. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305
8. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258
9. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL.et al.. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246
10. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-414
11. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008; 27: 5443-5453
12. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001; 14: 672-676
13. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y.et al.. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009; 15: 304-314
14. Brisbin S, Liu J, Boudreau J, Peng J, Evangelista M, Chin-Sang I. A role for C. elegans Eph RTK signaling in PTEN regulation. Dev Cell 2009; 17: 459-469
15. Ogg S, Ruvkun G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol Cell 1998; 2: 887-893
16. Solari F, Bourbon-Piffaut A, Masse I, Payrastre B, Chan AM, Billaud M. The human tumour suppressor PTEN regulates longevity and dauer formation in Caenorhabditis elegans. Oncogene 2005; 24: 20-27
17. Porte Jr D, Baskin DG, Schwartz MW. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005; 54: 1264-1276
18. Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G. daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 1997; 277: 942-946
19. Patel DS, Garza-Garcia A, Nanji M, McElwee JJ, Ackerman D, Driscoll PC.et al.. Clustering of genetically defined allele classes in the Caenorhabditis elegans DAF-2 insulin/IGF-1 receptor. Genetics 2008; 178: 931-946
20. Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007; 50: 2534-2543
21. Li W, Kennedy SG, Ruvkun G. daf-28 encodes a C. elegans insulin superfamily member that is regulated by environmental cues and acts in the DAF-2 signaling pathway. Genes Dev 2003; 17: 844-858
22. Halaschek-Wiener J, Khattra JS, McKay S, Pouzyrev A, Stott JM, Yang GS.et al.. Analysis of long-lived C. elegans daf-2 mutants using serial analysis of gene expression. Genome Res 2005; 15: 603-615
23. Murphy CT, McCarroll SA, Bargmann CI, Fraser A, Kamath RS, Ahringer J.et al.. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 2003; 424: 277-283
24. Tullet JM, Hertweck M, An JH, Baker J, Hwang JY, Liu S.et al.. Direct inhibition of the longevity-promoting factor SKN-1 by insulin-like signaling in C. elegans. Cell 2008; 132: 1025-1038
25. Dorman JB, Albinder B, Shroyer T, Kenyon C. The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 1995; 141: 1399-1406
26. Malone EA, Inoue T, Thomas JH. Genetic analysis of the roles of daf-28 and age-1 in regulating Caenorhabditis elegans dauer formation. Genetics 1996; 143: 1193-1205
27. Christensen R, de la Torre-Ubieta L, Bonni A, Colon-Ramos DA. A conserved PTEN/ FOXO pathway regulates neuronal morphology during C. elegans development. Development 2011; 138: 5257-5267
28. Pocock R, Hobert O. Oxygen levels affect axon guidance and neuronal migration in Caenorhabditis elegans. Nat Neurosci 2008; 11: 894-900
29. Adler CE, Fetter RD, Bargmann CI. UNC-6/Netrin induces neuronal asymmetry and defines the site of axon formation. Nat Neurosci 2006; 9: 511-518
30. Clark SG, Chiu C. C. elegans ZAG-1, a Zn-finger-homeodomain protein, regulates axonal development and neuronal differentiation. Development 2003; 130: 3781-3794
31. Mohamed AM, Chin-Sang ID. Characterization of loss-of-function and gain-offunction Eph receptor tyrosine kinase signaling in C. elegans axon targeting and cell migration. Dev Biol 2006; 290: 164-176
32. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA.et al.. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95: 13513-13518
33. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D.et al.. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-D950
34. Mahimainathan L, Choudhury GG. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 2004; 279: 15258-15268
35. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-1617
36. Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A.et al.. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal 2012; 5: ra18
37. Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN.et al.. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors. BMC Cancer 2011; 11: 123
38. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010; 29: 2517-2527
39. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK.et al.. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001; 98: 4622-4627
40. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M.et al.. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphataseindependent manner. Cell 2011; 144: 187-199
41. Nakdimon I, Walser M, Frohli E, Hajnal A. PTEN negatively regulates MAPK signaling during Caenorhabditis elegans vulval development. PLoS Genet 2012; 8: e1002881
42. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R.et al.. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992; 52: 3924-3930
43. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptordeficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 2002; 21: 8240-8250
44. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res 2012; 18: 40-50
45. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974; 77: 71-94
46. Chin-Sang ID, George SE, Ding M, Moseley SL, Lynch AS, Chisholm AD. The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate epidermal morphogenesis in C. elegans. Cell 1999; 99: 781-790
47. Mohamed AM, Boudreau JR, Yu FP, Liu J, Chin-Sang ID. The Caenorhabditis elegans Eph receptor activates NCK and N-WASP, and inhibits Ena/VASP to regulate growth cone dynamics during axon guidance. PLoS genetics 2012; 8: e1002513. Canada